Cryptic KMT2A/MLLT10 fusion detected by next-generation sequencing in a case of pediatric acute megakaryoblastic leukemia.
Child
Humans
Leukemia, Megakaryoblastic, Acute
/ genetics
In Situ Hybridization, Fluorescence
Transcription Factors
/ genetics
Myeloid-Lymphoid Leukemia Protein
/ genetics
Leukemia, Myeloid, Acute
/ genetics
Translocation, Genetic
High-Throughput Nucleotide Sequencing
Oncogene Proteins, Fusion
/ genetics
Acute megakaryoblastic leukemia
KMT2A/MLLT10 fusion
Next-generation sequencing
Pediatric AML
Journal
Cancer genetics
ISSN: 2210-7762
Titre abrégé: Cancer Genet
Pays: United States
ID NLM: 101539150
Informations de publication
Date de publication:
08 2023
08 2023
Historique:
received:
31
12
2022
revised:
09
06
2023
accepted:
08
07
2023
medline:
14
8
2023
pubmed:
22
7
2023
entrez:
21
7
2023
Statut:
ppublish
Résumé
KMT2A (11q23.3) gene rearrangements are found in acute leukemia and are associated with a poor or intermediate prognosis. MLLT10 is the fourth most common gene fusion partner for KMT2A. A reciprocal translocation t(10;11) is insufficient to produce an in-frame KMT2A/MLLT10 fusion, because the genes involved in the rearrangement have opposite transcriptional orientations. In order to bring KMT2A and MLLT10 into juxtaposition, complex rearrangements are required. Until now, conventional chromosome, fluorescence in situ hybridization (FISH), and reverse transcriptase-polymerase chain reaction (RT-PCR) studies have been used to detect KMT2A/MLLT10 fusions. However, conventional studies have limitations, such as poor and inconsistent resolution, when compared to next-generation sequencing (NGS). In this study, we report a pediatric patient with acute megakaryoblastic leukemia, in whom the cryptic KMT2A/MLLT10 fusion was not detected by KMT2A break-apart probe FISH and chromosome analysis, but detected by NGS. In this patient, NGS showed cryptic insertion of MLLT10 exons 9-24 into intron 9 of KMT2A, resulting in a KMT2A/MLLT10 fusion. Therefore, NGS is a valuable complementary option for the evaluation of structural aberrations, especially those with a cryptic size.
Identifiants
pubmed: 37478796
pii: S2210-7762(23)00038-8
doi: 10.1016/j.cancergen.2023.07.003
pii:
doi:
Substances chimiques
Transcription Factors
0
Myeloid-Lymphoid Leukemia Protein
149025-06-9
Oncogene Proteins, Fusion
0
MLLT10 protein, human
0
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
36-39Informations de copyright
Copyright © 2023. Published by Elsevier Inc.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare no competing interests.